Pfizer Total Long Term Liabilities 2010-2024 | PFE
Pfizer total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
- Pfizer total long term liabilities for the quarter ending September 30, 2024 were $83.707B, a 3.43% decline year-over-year.
- Pfizer total long term liabilities for 2023 were $89.418B, a 51.17% increase from 2022.
- Pfizer total long term liabilities for 2022 were $59.149B, a 3.58% decline from 2021.
- Pfizer total long term liabilities for 2021 were $61.342B, a 5.39% decline from 2020.
Pfizer Annual Total Long Term Liabilities
(Millions of US $) |
| 2023 |
$89,418 |
| 2022 |
$59,149 |
| 2021 |
$61,342 |
| 2020 |
$64,836 |
| 2019 |
$66,844 |
| 2018 |
$63,806 |
| 2017 |
$69,714 |
| 2016 |
$80,660 |
| 2015 |
$72,985 |
| 2014 |
$74,358 |
| 2013 |
$72,115 |
| 2012 |
$74,934 |
| 2011 |
$76,472 |
| 2010 |
$78,113 |
| 2009 |
$85,278 |
Pfizer Quarterly Total Long Term Liabilities
(Millions of US $) |
| 2024-09-30 |
$83,707 |
| 2024-06-30 |
$84,400 |
| 2024-03-31 |
$88,039 |
| 2023-12-31 |
$89,418 |
| 2023-09-30 |
$86,680 |
| 2023-06-30 |
$86,227 |
| 2023-03-31 |
$57,819 |
| 2022-12-31 |
$59,149 |
| 2022-09-30 |
$58,145 |
| 2022-06-30 |
$60,410 |
| 2022-03-31 |
$61,887 |
| 2021-12-31 |
$61,342 |
| 2021-09-30 |
$61,418 |
| 2021-06-30 |
$63,941 |
| 2021-03-31 |
$63,299 |
| 2020-12-31 |
$64,836 |
| 2020-09-30 |
$79,335 |
| 2020-06-30 |
$80,648 |
| 2020-03-31 |
$67,108 |
| 2019-12-31 |
$66,844 |
| 2019-09-30 |
$68,077 |
| 2019-06-30 |
$64,244 |
| 2019-03-31 |
$66,839 |
| 2018-12-31 |
$63,806 |
| 2018-09-30 |
$67,161 |
| 2018-06-30 |
$62,701 |
| 2018-03-31 |
$66,706 |
| 2017-12-31 |
$69,714 |
| 2017-09-30 |
$82,824 |
| 2017-06-30 |
$82,682 |
| 2017-03-31 |
$85,174 |
| 2016-12-31 |
$80,660 |
| 2016-09-30 |
$80,070 |
| 2016-06-30 |
$75,492 |
| 2016-03-31 |
$70,848 |
| 2015-12-31 |
$72,985 |
| 2015-09-30 |
$75,897 |
| 2015-06-30 |
$69,555 |
| 2015-03-31 |
$72,832 |
| 2014-12-31 |
$74,358 |
| 2014-09-30 |
$73,137 |
| 2014-06-30 |
$73,718 |
| 2014-03-31 |
$68,950 |
| 2013-12-31 |
$72,115 |
| 2013-09-30 |
$76,794 |
| 2013-06-30 |
$76,908 |
| 2013-03-31 |
$77,028 |
| 2012-12-31 |
$74,934 |
| 2012-09-30 |
$71,357 |
| 2012-06-30 |
$72,083 |
| 2012-03-31 |
$74,912 |
| 2011-12-31 |
$76,472 |
| 2011-09-30 |
$77,746 |
| 2011-06-30 |
$76,465 |
| 2011-03-31 |
$75,252 |
| 2010-12-31 |
$78,113 |
| 2010-09-30 |
$79,175 |
| 2010-06-30 |
$79,512 |
| 2010-03-31 |
$79,107 |
| 2009-12-31 |
$85,278 |
| 2009-09-30 |
$51,052 |
| 2009-06-30 |
$49,995 |
| 2009-03-31 |
$39,151 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
